Skip to main content
. 2023 Feb 7;18(2):e0281402. doi: 10.1371/journal.pone.0281402

Fig 3. The results of probabilistic sensitivity analysis.

Fig 3

(a) Scatterplot of the ICER between the anlotinib and sunitinib group. (b) The cost-effectiveness acceptability curves for anlotinb compared to the sunitinib at different willingness-to-pay thresholds.